NCT03678883 2026-04-039-ING-41 in Patients With Advanced CancersActuate Therapeutics Inc.Phase 2 Active not recruiting350 enrolled
NCT05179824 2025-05-06Tempus Priority Study: A Pan-tumor Observational StudyTempus AIActive not recruiting1,000 enrolled
NCT03525392 2023-12-12Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.IpsenPhase 1 Terminated14 enrolled 20 charts
NCT00423254 2010-08-03Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.Mannkind CorporationPhase 1 Completed12 enrolled